Reversible tumor progression induced by a dexamethasone course for severe covid-19 during immune checkpoint inhibitor treatment

HIGHLIGHTS

• who: Paul Gougis and colleagues from the Institut Universitaire Cancérologie, Galilée, France have published the paper: Reversible Tumor Progression Induced by a Dexamethasone Course for Severe COVID-19 during Immune Checkpoint Inhibitor Treatment, in the Journal: Diagnostics 2022, 12, 1933. of /2022/
• what: The authors report herein transient progression induced by dexamethasone for a patient treated with pembrolizumab for metastatic bladder cancer.

SUMMARY

Diagnostics2022, 2022,12, 12,1933 x FOR PEER REVIEW Diagnostics 22 of of55 3 3ofof55 4 of 5 In the case, however, the authors observed tumor . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.